Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Exclusive Article
Sell-Side Support Lifts RTX in 2026: 20% Upside IndicatedAuthored by Thomas Hughes. Posted: 4/22/2026. 
Key Points
- RTX pulled back following the Q1 release, with tepid guidance that forecast growth and margin strength.
- Analysts and institutions are accumulating this stock.
- New contracts and a growing backlog suggest outperformance is likely in upcoming quarters.
- Special Report: Elon Musk’s $1 Quadrillion AI IPO
RTX (NYSE: RTX) faces some headwinds in 2026, but analyst support, institutional backing and demand for its products are not among them. The primary drag — more accurately, a missing tailwind — is the pause in buyback activity following a January 2026 executive order from President Trump that restricts share repurchases and dividends at defense contractors identified as underperforming on military contracts. RTX was specifically named in connection with the order. That pause has caused the share count to tick up, although the increases are modest relative to the company's business growth, balance-sheet health and capacity to continue dividend payments.
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings.
Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds.
If any of these are in your portfolio, now is the time to review your positions. See the 5 stocks to avoid
Dividends remain intact, yielding about 1.4% with shares near April 2026 highs. The payout is modest relative to the broader market, but the metrics suggest it is reliable and likely to grow: the payout ratio sits just above 50% of earnings, earnings are rising, and the company has a five-year history of annual increases with a high single-digit compound annual growth rate. The main risk is that RTX either falls behind or overruns budgets on defense contracts, which could draw further regulatory scrutiny. Bullish Analyst Trends Support RTX Stock Price AdvanceRTX’s analyst trends are not wildly optimistic but demonstrate a solid base of support accumulating shares. The 22 analysts tracked by MarketBeat rate the stock a Moderate Buy. Coverage and price targets have both been rising. The late-April consensus implied roughly 8% upside, while more recent updates push toward the high end of the range. Those newer targets put the stock near $240 — roughly 20% above recent critical support — and the trend appears likely to continue. The company’s guidance update came in below Street consensus, but it still reflects a steady trajectory and ample free cash flow; management appears deliberately cautious. Institutional activity is similarly bullish. Institutions own about 87% of the shares and have been net buyers in 2026, buying at an approximately $2-to-$1 ratio in Q1 and accelerating purchases into early Q2. That accumulation should limit downside risk while the market seeks direction. Critical support sits near the 2026 lows around $190. Short interest is not a major factor, down from 2024 peaks to about 1%. RTX Stock Price Sets Up for Its Next Big MoveRTX price action shows signs of a market top, so further selling could deepen. However, with clear support near $190, the risk is somewhat contained and consolidation within the established trading range is a more likely near-term outcome. In that scenario, the stock may trade sideways until a new catalyst and a technical trigger emerge. 
The 30-day exponential moving average (EMA) is climbing and is converging with price action, reinforcing support near $190. This EMA reflects short-term trading flows, which look constructive. If the market advances with the EMA providing support, a rapid move to the range top is possible. Other indicators, including the stochastic oscillator and MACD, suggest the stock is approaching oversold territory, which supports the view that the bottom may be near even as bearish momentum persists. RTX Buzzes Into Buy Zone Following Strong Q1 ReleaseRTX reported a solid Q1, with strength across segments driven by commercial demand and defense-related orders. Net revenue of $22.1 billion rose nearly 9%, outpacing consensus by roughly 300 basis points, with Pratt & Whitney leading the gains. Pratt & Whitney grew about 11%, Raytheon grew 10%, and Collins Aerospace rose 5%, contributing to margin improvement. Adjusted net income grew 22%, adjusted EPS rose 21%, and free cash flow jumped 65% — margin gains were the standout takeaway. Guidance is the factor that prompted the post-release pullback. Management raised its revenue and earnings outlook but still fell short of consensus estimates. A key detail: backlog has swelled to roughly $271 billion, equivalent to more than 10 quarters of revenue at the Q1 pace. That backlog implies that execution — improving throughput, managing backlog, and continued investment in R&D — is the main path to outperformance. Valuation is the largest investor risk. Trading above about 28x earnings as of early Q2 2026, the stock sits at the high end of its historic range and already prices in a solid growth outlook. In this environment, execution is critical: delays, missteps or other operational setbacks would likely be reflected quickly in the share price. |
0 Response to "We're excited to have you on board"
Post a Comment